Peptide Functionalized Gold and Silver Nanoparticles Inhibit Respiratory Syncytial Virus (RSV) In Vitro

D.R. Baganizi, S. Bawage, A. Singh, P. Tiwari, V.A. Dennis, S.R. Singh
Alabama State University,
United States

Keywords: gold nanoparticles, silver nanoparticles, respiratory syncytial virus (RSV), anti-RSV peptides, virus inhibition


Human respiratory syncytial virus (RSV) is a major cause of severe upper and lower respiratory tract infections in infants, and in high-risk adults. Currently, there is no vaccine and the available therapeutic agents have limited efficacy. Metal Nanoparticles are good therapeutic agents due to their antibacterial and antiviral properties. In the present work, we demonstrate a high inhibitory activity of RSV infection in vitro using carboxylated Gold nanoparticles and Carboxyl-PEG-capped silver nanoparticles. Gold and silver nanoparticles were conjugated with 1) RSV Phosphoprotein P derived peptide targeting RSV replication by interfering with the binding of phosphoprotein P to nucleoprotein N (RSV-N); 2) a dendrimeric Heparan Sulfate-Binding Peptide (SB105-A10); and 3) with a small dendrimer-like peptide (RFI-641). The SB105-A10 and RFI-641 are known RSV entry inhibitors by competing for binding to cell surface HSPGs and via interactions with RSV fusion protein. Our results suggest that peptide conjugated Gold and Silver nanoparticles may be effective candidates as anti-RSV drugs that could inhibit RSV infection as well as prevent the spread of the virus from one cell to the other uninfected cells. This research was supported by funding from NSF-CREST grant (HRD-1241701) *Corresponding author: Shree R. Singh, PhD, Center for NanoBiotechnology & Life Sciences Research, Alabama State University, 1627 Hall Street, Montgomery, AL, 36104. Phone: (334)-229-4168: Email: